AnaptysBio (ANAB) News Today $24.69 +0.14 (+0.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$24.68 -0.01 (-0.02%) As of 08/1/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period IBD Rating Upgrades: AnaptysBio Shows Improved Price StrengthAugust 1 at 10:57 AM | msn.comAnaptysBio (NASDAQ:ANAB) Shares Down 9.8% - Here's WhyJuly 31 at 2:54 PM | marketbeat.comSkandinaviska Enskilda Banken AB publ Takes $623,000 Position in AnaptysBio, Inc. (NASDAQ:ANAB)July 31 at 6:41 AM | marketbeat.comCorton Capital Inc. Takes Position in AnaptysBio, Inc. (NASDAQ:ANAB)July 28, 2025 | marketbeat.comAnaptysBio (ANAB) Projected to Post Earnings on MondayJuly 28, 2025 | marketbeat.comAnalysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $47.13July 28, 2025 | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Price Target Raised to $80.00July 27, 2025 | americanbankingnews.comVictory Capital Management Inc. Acquires 71,980 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)July 26, 2025 | marketbeat.comJ.P. Morgan Keeps Their Buy Rating on AnaptysBio (ANAB)July 25, 2025 | theglobeandmail.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) StockJuly 25, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 25, 2025 | marketbeat.comAnaptysBio Earns RS Rating UpgradeJuly 24, 2025 | msn.comAnaptysBio: Potential Promise, But Some Cause For SkepticismJuly 14, 2025 | seekingalpha.comAnaptysBio, Inc. (ANAB) stock price, news, quote & history – Yahoo ...July 11, 2025 | nz.finance.yahoo.comAnaptysBio (NASDAQ:ANAB) Stock Price Up 7.6% - Here's WhyJuly 9, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Director Sells $493,202.25 in StockJuly 4, 2025 | insidertrades.comMoody Aldrich Partners LLC Takes Position in AnaptysBio, Inc. (NASDAQ:ANAB)July 4, 2025 | marketbeat.comInsider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) Director Sells 20,925 Shares of StockJuly 3, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by BrokeragesJune 30, 2025 | marketbeat.comHighMark Wealth Management LLC Takes $1.71 Million Position in AnaptysBio, Inc. (NASDAQ:ANAB)June 27, 2025 | marketbeat.comAssenagon Asset Management S.A. Lowers Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)June 16, 2025 | marketbeat.comBank of America Corp DE Lowers Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)June 15, 2025 | marketbeat.comStocks With Rising Relative Price Strength: AnaptysBioJune 13, 2025 | msn.comStocks With Rising Relative Price Strength: AnaptysBioJune 13, 2025 | msn.comAnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster PotentialJune 10, 2025 | seekingalpha.comStifel Nicolaus Remains a Buy on AnaptysBio (ANAB)June 7, 2025 | theglobeandmail.comAnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab AdvancementJune 6, 2025 | seekingalpha.comAnaptysBio (NASDAQ:ANAB) Trading Up 9.1% - What's Next?June 6, 2025 | marketbeat.comHC Wainwright & Co. Upgrades AnaptysBio (ANAB)June 5, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 4.5% - Should You Sell?June 5, 2025 | marketbeat.comAnaptys gains after updated data from mid-stage trial for arthritis therapyJune 5, 2025 | msn.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 5, 2025 | marketbeat.comJ&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agentJune 4, 2025 | msn.comAnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning PointJune 4, 2025 | benzinga.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up - Here's WhyJune 4, 2025 | marketbeat.comAnaptysBio’s Rosnilimab Shows ‘Best-in-Disease’ Profile in Phase 2b RA TrialJune 4, 2025 | insidermonkey.comAnaptysBio (NASDAQ:ANAB) Upgraded to Buy at HC WainwrightJune 4, 2025 | marketbeat.comAnaptysBio Rise 6% After Results From Rheumatoid Arthritis Treatment RosnilimabJune 3, 2025 | marketwatch.comStocks Generating Improved Relative Strength: AnaptysBioJune 3, 2025 | msn.comAnaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RAJune 3, 2025 | globenewswire.comMillennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)June 3, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Squarepoint Ops LLCJune 1, 2025 | marketbeat.comBeyond The Numbers: 5 Analysts Discuss AnaptysBio StockMay 30, 2025 | benzinga.comAnaptysBio (NASDAQ:ANAB) Shares Up 6.6% - Here's WhyMay 30, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Earns "Outperform" Rating from WedbushMay 30, 2025 | marketbeat.comVoloridge Investment Management LLC Trims Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)May 30, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up After Analyst UpgradeMay 29, 2025 | marketbeat.comAnaptysBio to Host Investor Call for Phase 2b RENOIR Trial Data on Rosnilimab for Rheumatoid ArthritisMay 29, 2025 | nasdaq.comGuggenheim Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $90.00May 29, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Two Sigma Investments LPMay 29, 2025 | marketbeat.com Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address ANAB Media Mentions By Week ANAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼0.920.45▲Average Medical News Sentiment ANAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼65▲ANAB Articles Average Week Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HUTCHMED News Today Kymera Therapeutics News Today Crinetics Pharmaceuticals News Today Immunovant News Today Alvotech News Today MorphoSys News Today Organon & Co. News Today NewAmsterdam Pharma News Today Recursion Pharmaceuticals News Today Ultragenyx Pharmaceutical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
